In connection with Nasdaq’s approval of the merger transaction, the combined company is required to meet Nasdaq’s Listing Rule 5110(a). More information for investors is available at Notice of Intent to Delist Warrants (Nasdaq: EYESW) Vivani headquarters are located in Emeryville, California. A recognized global leader in neuromodulation devices for blindness, Vivani is committed to identifying and executing the best strategic options that will enable its innovative technologies to treat the broadest population of sight-impaired individuals. before the merger was consummated and the name was changed to Vivani Medical, Inc. The visual prosthesis developments are a continuation of the work which has been pursued at Second Sight Medical Products, Inc. More information is available at Vivani is also developing implantable visual prostheses that are intended to deliver useful artificial vision to blind individuals. The company’s lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with Type 2 diabetes. These drug implants, designed to deliver minimally fluctuating drug profiles, will address drug non-adherence which is one of the leading reasons for sub-optimal clinical benefit associated with oral and injectable products that treat chronic diseases. was a privately held biopharmaceutical company developing drug implants which utilize its proprietary NanoPortal drug implant technology. Prior to the merger, Nano Precision Medical, Inc. The Company leverages proprietary technologies to develop and commercialize drug and device implants that treat patients with chronic diseases with high unmet medical need. Vivani Medical, Inc., which will soon trade under the Nasdaq ticker VANI, is the combination of Nano Precision Medical, Inc. We believe a six-month implant can provide an important alternative for non-adherent patients and the physicians who treat them.” Medication non-adherence for Type II diabetes patients taking oral or injectable therapies is approximately 50%. We anticipate that the first application of our technology will be ready to begin evaluation in humans around the end of this year with NPM-119. “Our proprietary NanoPortal technology has broad potential across a wide range of therapeutic molecules. We are also committed to identifying a sustainable path forward to bring Second Sight’s Orion Visual Cortical Prosthesis System to individuals who are blind due to a wide range of causes,” said Adam Mendelsohn, Ph.D., Chief Executive Officer of the Company. “The completion of the merger marks a significant milestone for Vivani as we continue to grow the company with a strong team, sufficient funding, and an attractive group of investors who support our pursuit to develop and commercialize a new portfolio of miniaturized drug implants which can effectively address medication non-adherence, a major challenge in the treatment of chronic disease, including Type II diabetes. Adam Mendelsohn, and his leadership team of seasoned industry veterans. The Company will operate under the leadership of NPM’s CEO, Dr. Upon completion of the merger, the Company has approximately $55 million in cash to advance the development of Vivani’s portfolio, which includes lead asset NPM-119 (exenatide implant), into clinical-stage development for the treatment of patients with Type 2 diabetes and to identify and execute strategic options to advance it’s clinical-stage Orion visual prosthetic device to treat individuals with blindness due to a wide range of underlying causes. ThinkEquity acted as the financial advisor to Second Sight in connection with the merger. The Company’s common stock will trade on The Nasdaq Capital Market under the symbol “VANI”. In connection with the merger, Second Sight changed its name to Vivani Medical, Inc. NPM is a biopharmaceutical business which develops miniaturized, subdermal drug implants utilizing its proprietary NanoPortal™ technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. LOS ANGELES-( BUSINESS WIRE)-Second Sight Medical Products, Inc.(NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today the completion of its merger with Nano Precision Medical, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |